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Abstract 
AIM: This study was designed as a preliminary investigation of safety and efficacy of LifePearl, polyethylene 
glycol microspheres loaded with doxorubicin for treatment of locally untreatable (i.e., unresectable and not 
suitable for local thermal ablation) hepatocellular carcinoma (HCC). 
MATERIAL AND METHODS: Patients with locally untreatable HCC (mono- or bilobar disease, ECOG 
performance status 0-1, Chilg-Pugh score < 11) were analysed for this single arm Unicenter retrospective study. 
All the information were acquired through our local hospital information system. DEB-TACE was performed with 
100-200 microns LifePearl loaded with 75-150 mg of doxorubicin depending on tumour size. One interventional 
radiologist with experience of more than 350 TACE procedures and one fellow in radiology performed all 
embolisations. 
RESULTS: Twenty subjects with 29 tumours were treated (mean age 66.2 years). Child-Pugh status was A for 12 
pts. (60%), B for 6 pts. (30%) and C for 2 pts. (10%). Three patients had insignificant ascites. Most patients (70%) 
underwent < 3 DEB-TACE procedures. Average doxorubicin dose was 71.1 mg per procedure. One patient had 
procedure-related SAE (acute pancreatitis) within the postembolization period which was induced due to non-
target embolisation of the superior pancreaticoduodenal artery. Six-month freedom from procedure-related SAE or 
death was 95% (one necrotizing pancreatitis). Tumor response or stable disease was achieved in 95% (19/20) of 
subjects. Freedom from tumor progression or death at 6 months was 95%. One-year survival rate was 90% 
overall. 
CONCLUSION: The results from this investigation suggest that LifePearl microspheres, Terumo loaded with 
doxorubicin can provide an excellent local tumour control with very few side effects in a relatively homogeneous 
group of patients with locally untreatable HCC. 
 
 
 
 
 
 
Introduction 
 
Patients with locally untreatable HCC (i.e., 
unresectable and not suitable for local thermal 
ablation) have few treatment options [1]. Systemic 
chemotherapy with sorafenib has shown to modestly 
prolong survival in patients with advanced stage 
disease [1], [2] and transarterial chemoembolization 
(TACE) is recommended for patients in intermediate 
stage disease [1]. Meta-analyses have shown that 
TACE performed with doxorubicin-loaded beads has 
similar efficacy but fewer side effects than 
conventional lipiodol-based TACE [3], [4]. So far there 
are four types of drug-eluting microspheres on the 
market. The first three types are based on polyvinyl 
alcohol (PVA) and the last one developed are 
LifePearl made from polyethylene glycol. In our 
centre, we started using this polyethylene glycol 
platform since 2016. So far, there are only a couple of 
preliminary studies in the literature, regarding the 
safety profile of polyethylene glycol particles.  
This investigation was designed in a 
retrospective fashion to evaluate safety and efficacy of 
LifePearl microspheres loaded with doxorubicin for 
DEB-TACE treatment of locally untreatable 
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hepatocellular carcinoma, specifically the size of 100 
and 200 microns and 75-150 mg of doxorubicin. 
 
 
Material and Methods 
 
Study design 
This investigation represents a retrospective, 
Unicenter, single-arm feasibility study of 
chemoembolization with 100 and 200 microns 
doxorubicin-loaded LifePearl microparticles for 
treatment of locally unresectable HCC. 
 
Study Patients 
Patients eligible for the study were adults with 
a confirmed diagnosis of HCC according to the 
European Association of Study of the Liver (EASL) 
criteria [6] and were staged according to BCLC criteria 
[1]. Eastern Cooperative Oncology Group (ECOG) [7] 
performance status was 0 and 1, and we included 
patients with Child-Pugh score of < 11 points (i.e. A, B 
or C 10) [8]. Twenty patients with 29 tumours were 
enrolled. Tumor size ranged between 1.5-15 cm in 
largest diameter (mean diameter = 5.67 cm) both 
mono or bilobar disease. Lack of main portal vein 
trunk or common bile duct invasion was confirmed 
with preprocedural multidetector computed 
tomography (MDCT). Patients had laboratory values 
in the following ranges: white blood cell count > 
3500/ml, absolute neutrophil count > 1500 cells/ml, 
INR < 1.8, partial thromboplastin time < 38 s, platelet 
number > 5 x 10
4
 ml, blood bilirubin level < 20 mmol/L, 
aspartate aminotransferase (AST) level and alanine 
aminotransferase (ALT) within five times of normal 
range of each organ, serum creatinine level < 2.5 
mg/dL, hemoglobin > 8.0 g/dL, and alkaline 
phosphatase < 630 IU/L.  
 
Embolisation Procedure 
LifePearl microspheres are polyethylene 
glycol particles that can be loaded with anthracyclines 
such as doxorubicin, epirubicin, idarubicin or other 
chemotherapeutic drugs, such as irinotecan [5], [9], 
[10], [11]. Patients in this study were treated with 100 
and 200 microns diameter LifePearl microspheres, 
which are calibrated to ± 25 microns. One 2 ml 
syringe of microspheres can be loaded with up to 75 
mg of doxorubicin, with little shrinkage observed after 
drug loading [9]. Doxorubicin loading was performed 
according to the manufacturer’s instructions. A 
procedural doxorubicin dose of 75 mg/m
2 
body 
surface area
 
was targeted. A minimum of two 
treatments per lesion, separated by 4 weeks interval 
were performed. Thus, patients with bilobar disease 
were treated with at least 4 sessions (two per liver 
lobe). 
Chemoembolization procedures were 
performed with antibiotic prophylaxis, analgesic and 
antiemetic medication at the physician’s discretion. 
Angiography of the hepatic and mesenteric arteries 
was performed before chemoembolization to confirm 
anatomical eligibility and identify tumour feeder 
arteries. Hepatic segmental or subsegmental arteries 
supplying the lesion were selectively catheterised with 
microcatheter while ensuring sufficient flow to the 
tumour, and a mixture of 100 or 200 microns of 
doxorubicin-loaded microspheres and non-ionic 
contrast agent was slowly injected. Bland 
microspheres were also used in some cases if blood 
stasis was not achieved after the delivery of the 
desired drug dose. 
 
Safety and efficacy endpoints 
Safety was observed as freedom from severe 
adverse events (SAE) at 30 days and 6 months, and 
efficacy as freedom from tumour progression at 6 
months after chemoembolization. Secondary points 
were the rate of local tumour control and 12-month 
survival. 
Adverse event monitoring was observed and 
recorded during the treatment and follow-up phases. 
Tumour imaging (contrast-enhanced CT) was 
performed, and measurements were taken within 4 
weeks before the first DEB-TACE procedure 
(baseline) and 4 weeks following every embolisation 
procedure. Repeat DEB-TACE procedures were 
performed when follow-up imaging studies showed 
residual enhancement until complete response 
according to the modified Response Evaluation 
Criteria in Solid Tumors (mRECIST) criteria was 
achieved. Imaging was repeated at 4 to 6 weeks 
intervals to determine the need for additional DEB-
TACE procedures and was scheduled to be 
performed 3 and 6 months following the last DEB-
TACE procedure and 12 months from the initial 
treatment. Clinical and laboratory assessments were 
also repeated at each of these visits. Tumour 
response was assessed based on mRECIST criteria 
[12]. ”Best overall response” was defined as the 
smallest measurement of hypervascularized tumour 
tissue recorded from the start of treatment until 
disease progression/ recurrence. Images were 
evaluated by the interventional radiologist who 
performed the DEB-TACE procedures. 
 
 
Results 
 
From February 2016 to July 2018, 20 patients 
with 29 tumours were treated at our department for 
interventional radiology. Patient and lesion 
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characteristics are summarized in Table 1. 
There was no statistically significant 
difference among patient groups regarding the 
aetiology of cirrhosis (p > 0.05). ECOG performance 
status of 0 is significantly more included than ECOG 1 
(p < 0.05).  
Table 1: Baseline patient characteristics  
Characteristic N (%) 
(N = 20) 
P 
Sex (male/female) 15/5 P = 0.0016 
Age, years (median, range) 66.2 (55-80)  
Aetiology of cirrhosis   
Alcohol abuse 5 (25.0)  
P > 0.05 Hepatitis B 7 (35.0) 
Hepatitis C 0 (0) 
Unknown/other 8 (40.0) 
Child-Pugh classification   
A 10 (50.0)  
P = 0.0058 
P = 0.0258 
B 8 (40.0) 
C 2 (10.0) 
ECOG performance status   
0 16 (80.0) P = 0.0001 
 1 4 (20.0) 
BCLC classification   
A 12 (60.0) P = 0.0009 
 B 6 (30.0 
C 2 (10.0) 
Prior liver surgery 1 (5.0)  
Prior RFA therapy 1 (5.0)  
Liver lobes involved   
1 (Monolobar HCC) 17 (85.0) P = 0.0000 
 2 (Bilobar HCC) 3 (15.0) 
Tumor size (largest diameter; 
N = 29) 
  
< 3 cm 10 (34.5)  
P > 0.05 3 ≤ 5 cm 5 (17.2) 
5 ≤ 10 cm  9 (31.0) 
> 10 cm 5 (17.2) 
Range 1-15 cm  
 
Most of the patients (85%) had monolobar 
disease (P value < 0.05) and 90% had early or 
intermediate stage HCC, BCLC A and B, significantly 
more than C (P < 0.05). Only two patients had prior 
therapy (surgery or radiofrequency ablation) before 
chemoembolization; none had systemic 
chemotherapy. 
All patients that were included in the study 
underwent at least two successful DEB-TACE 
procedures, except one patient who had one 
chemoembolization only because we were confident 
that we achieved a complete response after the first 
TACE which was confirmed with several consecutive 
imaging controls.  
 
Safety 
By 30 days from their first embolisation 
procedure with drug-loaded microspheres, 95% (n = 
19) of patients remained free from procedure-related 
severe adverse events. One patient (5%) experienced 
acute pancreatitis which was confirmed by clinical 
signs, laboratory tests and imaging studies. After 
carefully reviewing the DEB-TACE procedure in this 
patient we realised that it was due to reflux of drug-
loaded microparticles in the superior 
panreatoduodenal artery because tumor was supplied 
from the gastroduodenal artery and partially from the 
right hepatic artery. The patient had a history of 
cirrhosis of the liver, previous liver surgery due to 
HCC, Hepatitis B infection, portal hypertension, 
chronic erosive gastritis and presented with BCLC B 
HCC. This complication was treated with conservative 
medical treatment and prolonged hospitalisation. The 
patient recovered and was discharged from hospital 
10 days later. Prolonged postembolization syndrome 
occurred in 6 patients, followed by moderate 
abdominal pain, slightly elevated temperature, 
nausea/vomiting and loss of appetite. These patients 
remained in the hospital for 3 nights and then were 
discharged in good clinical condition. The occurrence 
of post-embolisation syndrome symptoms after 
embolisation procedures is summarised in Table 2. 
Post-embolization syndrome events were grade 1 or 
2. 
Table 2: Occurrence of post-embolisation syndrome following 
DEB-TACE procedures 
 1
st
 DEB-
TACE 
(N = 20) 
2
nd
 DEB-
TACE 
(N = 19) 
3
rd
 DEB-
TACE 
(N = 10) 
4
th
 DEB-
TACE 
(N = 3) 
5
th
 DEB-
TACE 
(N = 2) 
Postembolization 
syndrome, n (%) 
11 (55.0) 8 (42.1) 7 (70.0) 2 (66.6) 1 (50.0) 
Abdominal pain 7 (35.0) 4 (21.0) 6 (60.0) 1 (33.3) 0 (0) 
Nausea/vomiting 1 (5.0) 2 (10.5) 1 (10.0) 1 (33.3) 0 (0) 
Fever 1 (5.0) 2 (10.5) 3 (30.0) 0 (0) 1 (50.0) 
 
According to the index of dynamics, a 
decrease in postembolization syndrome is registered 
from first to third DEB-TACE for 36.4%, and first to 
fifth DEB-TACE for 90.9%.  
By 6 months from their first DEB-TACE 
procedure, 95% (N = 19) of patients were free from 
procedure-related serious adverse events or death. All 
patients survived at least 6 months after treatment. 
Imaging to evaluate tumour response was 
available for all 20 patients. According to mRECIST 
criteria for best response, complete response was 
achieved in 10 patients (50%), partial response in 6 
(30%), stable disease in 3 (15%) and progressive 
disease in 1 (5%). Significantly more patients had 
complete response versus stable and progressive 
disease (P = 0.0181 and P = 0.0014). At 6 months, 
95% of patients were free from tumour progression or 
death. The one patient who had tumour progression 
had three embolisation procedures before progression 
was observed. At 6 months, 95% of patients were free 
from tumour progression or death. The one patient 
who had tumour progression had three embolisation 
procedures before progression was observed. 
One-year survival rate was 90% (18/20). One 
death was due to other comorbidities, not tumour 
itself, the other one was due to progressive HCC 
disease. Both of these patients were staged as BCLC 
C disease before treatment. 
 
 
Discussion 
 
The results from this study demonstrate a 
high rate of local tumour control and only one severe 
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adverse event among patients treated with 
doxorubicin-loaded PEG microspheres. In a 
preliminary single-center retrospective study by 
Veloso Gomez et al., [21] in 302 patients with HCC, 
treated with polyethene glycol microspheres, more 
than 80% of patients had objective tumour response 
and the one-year survival rate was 93.5%. However, 
in this study, a large number of patients (142) had 
Barcelona Clinic Liver Cancer stage A disease and 
134 had BCLC stage B disease which is a good 
prognostic factor for HCC patients. Also, mean index 
tumour size in this study was 3.7 cm, and in our study 
median tumour diameter was 5.7 cm. The incidence of 
serious adverse events or Grade 3-4 toxicities 
following doxorubicin-eluting embolic therapy for HCC 
has generally been low in previous studies [13], [14],  
[15] and was comparably low in our investigation. For 
example, Prajapati et al., [13] reported an overall 
adverse event rate of 30% within 30 days of 
embolisation, with the majority of complications Grade 
1-2 and no Grade 4 toxicities in a retrospective study 
od 121 patients. In a randomised study, approximately 
24% of 93 patients treated with drug-eluting embolic 
agent reported serious adverse events within 30 days, 
and two patients died [14]. In this study, no deaths or 
systemic toxicities occurred within 30 days, and only 1 
patient had procedure-related serious adverse event. 
Although the heterogeneous nature of HCC patients 
characteristics, variable treatment regimes, and 
evaluation criteria across studies limit comparisons 
between studies, results from previous studies of 
doxorubicin-loaded microspheres treatment of HCC 
provide background for the findings observed in our 
investigation. 
Post-embolization syndrome, or symptoms 
like abdominal pain, nausea, vomiting, and fever has 
been reported in 5-100% of patients in previous 
studies [5], [13], [14], [15], [16], [17]. Richter et al. 
reported tumour response rate with complete or partial 
tumour response observed in 67% of patients in 
MIRACLE I study [20]. In our study, we found that 
80% of the patients had a complete or partial 
response to intraarterial therapy and only 1 patient 
(5%) displayed tumour progression during follow up. 
The one-year survival rate in MIRACLE I study was 
56% with a greater rate among patients with Child-
Pugh A liver cirrhosis (75%) [20]. In our study, one-
year survival rate was 90%, but compared to the 
patients in MIRACLE I, in our study Child-Pugh A and 
B cirrhosis was found in 90% of patients. We had 2 
patients with no significant ascites while in MIRACLE 
I, 10 patients had severe ascites. Previously reported 
one-year survival rates among different studies varied 
between 58 and 92% [5], [15], [18], with stratifying 
factors such as the presence of ascites and Child-
Pugh classification of B or C associated with poorer 
survival [13], [18], [19]. The proportion of patients with 
ascites or liver function with Child-Pugh B and C are 
relatively low in our group of patients but not very 
different than other studies (i.e., no patients with 
ascites or Child-Pugh C were included in the studies 
from Reyes et al., [15] or Malagari et al., [5]. 
The limitations of this study are that it is a 
retrospective one and that the sample size is relatively 
small. Study sample is with relatively homogeneous 
clinical characteristics. The results from this 
investigation suggest that LifePearl polyethylene 
glycol microspheres, when loaded with doxorubicin, 
can provide excellent local tumour control with a very 
low rate of procedure-related complications in a well-
selected group of patients with locally untreatable 
HCC. 
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